Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Response to Tetangco and Hanauer

Seth R Shaffer^1,2,3, David T Rubin¹

¹Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, Illinois, USA.

The American Journal of Gastroenterology

|June 8, 2021

Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Healthcare professionals' knowledge, attitudes, and practice with addressing sexual health among people living with inflammatory bowel disease: A UK cross-sectional survey.

Inflammatory bowel diseases·2026

Same author

Combined bowel urgency, clinical outcomes, and quality of life improvement in mirikizumab-treated ulcerative colitis: a step toward comprehensive disease management.

Crohn's & colitis 360·2026

Same author

Dual-targeted therapy with risankizumab and upadacitinib in medically complex Crohn's disease.

Crohn's & colitis 360·2026

Same author

Impact of Upadacitinib on Cardiovascular Events and Lipid Values in Older Inflammatory Bowel Disease Patients with Baseline Cardiovascular Risk.

The American journal of gastroenterology·2026

Same author

Time to rethink washout periods in inflammatory bowel disease clinical trials: an international Delphi consensus.

Journal of Crohn's & colitis·2026

Same author

Evaluation of a pharmacist directed treat to target approach in patients with inflammatory bowel disease receiving upadacitinib or risankizumab.

Crohn's & colitis 360·2026